Key Takeaways
- • Major hedge funds including Bridgewater Associates, Tiger Global Management, and Discovery Capital significantly increased Big Tech exposure in Q2 2026, reversing earlier-year selling pressure driven by tariff volatility and AI valuation concerns.
- • Hedge fund leverage surged to near one-year highs as of late February 2026, with net equity sales orders hitting their highest level since President Trump announced import tariffs in April 2025, signaling aggressive repositioning across mega-cap and AI-related equities.
- • 86% of hedge funds now deploy generative AI for investment processes, but the strategic focus is shifting from AI-driven signal generation toward capital allocation and execution, creating a transparency gap where algorithms execute trades in milliseconds without explainable decision logic.
- • Hedge funds rotated out of traditional laggards including aerospace/defense, consumer/retail, and financial stocks, while accumulating positions in technology, energy, healthcare, and staples, alongside selective bets on depressed names like UnitedHealth Group (down 46% in 2026).
- • Software and semiconductor stocks remain positioning extremes, with JPMorgan noting historic sell-downs in software followed by selective rebounds, though rotation momentum appeared to slow or reverse by late February 2026.
Summary
Wall Street's largest hedge funds have executed a sharp tactical reversal on technology equities during the first half of 2026, dramatically increasing exposure to Big Tech after months of sustained selling pressure. Bridgewater Associates, Tiger Global Management, and Discovery Capital all meaningfully expanded their positions in mega-cap technology companies during the June quarter, marking a significant shift from earlier in the year when tariff-fueled market volatility and investor skepticism around artificial intelligence valuations had triggered broad sell-offs in the "Magnificent Seven" cohort. The broader S&P 500 gained approximately 10% year-to-date through mid-year, with nearly one-third of the index's market capitalization now concentrated in the largest technology companies that have driven the recovery.
The tactical repositioning intensified in late February 2026, with hedge funds deploying increased leverage to accumulate mega-cap technology stocks and AI-exposed equities after weeks of sustained selling. Goldman Sachs data revealed that hedge fund leverage had climbed from February 14 levels and was approaching its highest point in roughly twelve months, while net equity sales orders reached their peak since Trump announced sweeping tariff measures in April 2025. JPMorgan's client notes indicated that funds were simultaneously buying the most valuable tech stocks alongside companies perceived as vulnerable to artificial intelligence disruption, though positioning between semiconductor and software segments remained historically stretched across global, U.S., and European markets.
Beyond technology, hedge funds demonstrated selective opportunism in structurally challenged names. Discovery Capital and Lone Pine Capital, alongside Michael Burry's Scion Asset Management and Soros Fund Management, initiated or expanded positions in UnitedHealth Group despite the insurer's 46% year-to-date decline, driven by rising cost pressures, Department of Justice investigation, cyberattack exposure, and reputational fallout from the shooting death of former CEO Brian Thompson in December 2025. This selective value hunting outside pure-technology exposure suggests funds are balancing momentum-driven technology allocation with contrarian positioning in beaten-down healthcare assets.
A critical structural shift has emerged in how hedge funds deploy artificial intelligence itself as an investment tool. Eighty-six percent of hedge funds now utilize generative AI in portfolio processes, yet the strategic application has evolved from preliminary signal generation toward direct capital allocation and trade execution. However, this advancement presents an emerging governance challenge: as AI systems execute trades in milliseconds with increasing autonomy, many portfolio managers report deferring excessively to algorithmic outputs without adequate explainability frameworks. Industry participants, including managers at H2O Asset Management, have flagged that the competitive advantage is no longer derived from simply deploying AI infrastructure—which is becoming commoditized—but rather from maintaining disciplined decision-making authority over allocation and execution in conditions of fundamental uncertainty.
The tactical repositioning intensified in late February 2026, with hedge funds deploying increased leverage to accumulate mega-cap technology stocks and AI-exposed equities after weeks of sustained selling. Goldman Sachs data revealed that hedge fund leverage had climbed from February 14 levels and was approaching its highest point in roughly twelve months, while net equity sales orders reached their peak since Trump announced sweeping tariff measures in April 2025. JPMorgan's client notes indicated that funds were simultaneously buying the most valuable tech stocks alongside companies perceived as vulnerable to artificial intelligence disruption, though positioning between semiconductor and software segments remained historically stretched across global, U.S., and European markets.
Beyond technology, hedge funds demonstrated selective opportunism in structurally challenged names. Discovery Capital and Lone Pine Capital, alongside Michael Burry's Scion Asset Management and Soros Fund Management, initiated or expanded positions in UnitedHealth Group despite the insurer's 46% year-to-date decline, driven by rising cost pressures, Department of Justice investigation, cyberattack exposure, and reputational fallout from the shooting death of former CEO Brian Thompson in December 2025. This selective value hunting outside pure-technology exposure suggests funds are balancing momentum-driven technology allocation with contrarian positioning in beaten-down healthcare assets.
A critical structural shift has emerged in how hedge funds deploy artificial intelligence itself as an investment tool. Eighty-six percent of hedge funds now utilize generative AI in portfolio processes, yet the strategic application has evolved from preliminary signal generation toward direct capital allocation and trade execution. However, this advancement presents an emerging governance challenge: as AI systems execute trades in milliseconds with increasing autonomy, many portfolio managers report deferring excessively to algorithmic outputs without adequate explainability frameworks. Industry participants, including managers at H2O Asset Management, have flagged that the competitive advantage is no longer derived from simply deploying AI infrastructure—which is becoming commoditized—but rather from maintaining disciplined decision-making authority over allocation and execution in conditions of fundamental uncertainty.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.